Tyr Pharma stock rated Hold after mixed trial results for efzofitimod; promising secondary data, but there remains uncertainty. Find out why ATYR is a Hold.

When feckless opinions driven by ideology become the basis for crafting government laws and policies, everyone suffers.

Stock markets are in trouble if soft U.S. economic data along with signs of weakness abroad put worries about global ...

Exercising less, skipping parties and struggling at work: the expectation of chronic pain and itching can lead to avoidance ...

A federal judge ordered the agency to give detainees at 26 Federal Plaza adequate space, hygiene supplies and the chance to ...

Dr. Kurt Miceli, medical director for the advocacy group Do No Harm, presented at the CDC’s twice-yearly conference to update U.S. medical codes to include side effects for detransitioners, or those ...

The Biden Administration insisted on calling the January 6 riot an armed insurrection for years, and targeted parents who ...

Data can expose injustice, but it can also be turned into a tool of control. How do we know when data collection is helpful ...

The development of artificial intelligence in medicine and pharmacy has been discussed for years, but there is still no ...

Many investors have fallen in love with Hims & Hers (HIMS) because weight-loss drugs have been a powerful catalyst for this emerging tele-health company’s initial growth. HIMS kept at weight loss ...

New research from Yale SOM’s Mushfiq Mobarak shows that the violence and looting in rice-growing areas is tied to rice prices ...

A system that generates images by inducing random fluctuations in a laser beam could slash energy use compared with standard ...